Literature DB >> 25946358

A comparison of the Xpert(®) MTB/RIF and GenoType(®) MTBDRplus assays in Georgia.

N Bablishvili1, N Tukvadze1, Z Avaliani1, H M Blumberg2, R R Kempker2.   

Abstract

Few studies have directly compared the performance of rapid molecular diagnostic tests for tuberculosis (TB). We found that the commercially available molecular diagnostic tests Xpert(®) MTB/RIF and GenoType(®) MTBDRplus both provided timely and accurate results compared to conventional phenotypic tests in detecting TB and rifampicin resistance.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25946358      PMCID： PMC4562278          DOI： 10.5588/ijtld.14.0867

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN： 1027-3719            Impact factor:   2.373


  8 in total

1.  Comparison of Xpert MTB/RIF with line probe assay for detection of rifampin-monoresistant Mycobacterium tuberculosis.

Authors:  Syed Beenish Rufai; Parveen Kumar; Amit Singh; Suneel Prajapati; Veena Balooni; Sarman Singh
Journal:  J Clin Microbiol       Date:  2014-03-19       Impact factor: 5.948

Review 2.  Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.

Authors:  Karen R Steingart; Ian Schiller; David J Horne; Madhukar Pai; Catharina C Boehme; Nandini Dendukuri
Journal:  Cochrane Database Syst Rev       Date:  2014-01-21

3.  The diagnostic performance of the GenoType MTBDRplus version 2 line probe assay is equivalent to that of the Xpert MTB/RIF assay.

Authors:  M Barnard; N C Gey van Pittius; P D van Helden; M Bosman; G Coetzee; R M Warren
Journal:  J Clin Microbiol       Date:  2012-09-12       Impact factor: 5.948

4.  Significant clinical impact of a rapid molecular diagnostic test (Genotype MTBDRplus assay) to detect multidrug-resistant tuberculosis.

Authors:  Maia Kipiani; Veriko Mirtskhulava; Nestani Tukvadze; Matthew Magee; Henry M Blumberg; Russell R Kempker
Journal:  Clin Infect Dis       Date:  2014-08-04       Impact factor: 9.079

Review 5.  Mechanisms of drug resistance in Mycobacterium tuberculosis.

Authors:  Y Zhang; W W Yew
Journal:  Int J Tuberc Lung Dis       Date:  2009-11       Impact factor: 2.373

Review 6.  Challenges to the global control of tuberculosis.

Authors:  Chen-Yuan Chiang; Catharina Van Weezenbeek; Toru Mori; Donald A Enarson
Journal:  Respirology       Date:  2013-05       Impact factor: 6.424

7.  Use of a molecular diagnostic test in AFB smear positive tuberculosis suspects greatly reduces time to detection of multidrug resistant tuberculosis.

Authors:  Nestani Tukvadze; Russell R Kempker; Iagor Kalandadze; Ekaterina Kurbatova; Michael K Leonard; Rusudan Apsindzelashvili; Nino Bablishvili; Maia Kipiani; Henry M Blumberg
Journal:  PLoS One       Date:  2012-02-09       Impact factor: 3.240

8.  Clinical characteristics and treatment outcomes of patients with low- and high-concentration isoniazid-monoresistant tuberculosis.

Authors:  Tsai-Yu Wang; Shu-Min Lin; Shian-Sen Shie; Pai-Chien Chou; Chien-Da Huang; Fu-Tsai Chung; Chih-His Kuo; Po-Jui Chang; Han-Pin Kuo
Journal:  PLoS One       Date:  2014-01-22       Impact factor: 3.240
  8 in total
  7 in total

1.  Impact of gyrB and eis Mutations in Improving Detection of Second-Line-Drug Resistance among Mycobacterium tuberculosis Isolates from Georgia.

Authors:  N Bablishvili; N Tukvadze; E Shashkina; B Mathema; N R Gandhi; H M Blumberg; R R Kempker
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

2.  Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults.

Authors:  Mikashmi Kohli; Ian Schiller; Nandini Dendukuri; Mandy Yao; Keertan Dheda; Claudia M Denkinger; Samuel G Schumacher; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2021-01-15

3.  Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults.

Authors:  David J Horne; Mikashmi Kohli; Jerry S Zifodya; Ian Schiller; Nandini Dendukuri; Deanna Tollefson; Samuel G Schumacher; Eleanor A Ochodo; Madhukar Pai; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2019-06-07

Review 4.  Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance.

Authors:  Mikashmi Kohli; Ian Schiller; Nandini Dendukuri; Keertan Dheda; Claudia M Denkinger; Samuel G Schumacher; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2018-08-27

5.  Xpert MTB/RIF and Xpert Ultra assays for screening for pulmonary tuberculosis and rifampicin resistance in adults, irrespective of signs or symptoms.

Authors:  Adrienne E Shapiro; Jennifer M Ross; Mandy Yao; Ian Schiller; Mikashmi Kohli; Nandini Dendukuri; Karen R Steingart; David J Horne
Journal:  Cochrane Database Syst Rev       Date:  2021-03-23

Review 6.  Accuracy of line probe assays for the diagnosis of pulmonary and multidrug-resistant tuberculosis: a systematic review and meta-analysis.

Authors:  Ruvandhi R Nathavitharana; Patrick G T Cudahy; Samuel G Schumacher; Karen R Steingart; Madhukar Pai; Claudia M Denkinger
Journal:  Eur Respir J       Date:  2017-01-18       Impact factor: 16.671

7.  Pulmonary function and respiratory health after successful treatment of drug-resistant tuberculosis.

Authors:  Sergo A Vashakidze; Jordan A Kempker; Nino A Jakobia; Shota G Gogishvili; Ketino A Nikolaishvili; Leila M Goginashvili; Matthew J Magee; Russell R Kempker
Journal:  Int J Infect Dis       Date:  2019-03-05       Impact factor: 3.623
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.